Baudax Bio, Inc. (BXRXQ)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT
Market Cap52.00
Revenue (ttm)1.27M
Net Income (ttm)-7.61M
Shares Out52.46M
EPS (ttm)-1.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1
Average Volume1,762
Open0.0001
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Beta20.05
RSI29.13
Earnings DateFeb 21, 2025

About United States Steel

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB revers... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol BXRXQ
Full Company Profile

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.

Financial Statements

News

There is no news available yet.